This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reddy, J. A. Articles by Leamon, C. P. Search for Related Content PubMed PubMed Citation Articles by Reddy, J. A. Articles by Leamon, C. P.

Folate Receptor–Specific Antitumor Activity of EC131, a Folate-Maytansinoid Conjugate

¹ Endocyte, Inc., West Lafayette, Indiana and ² ImmunoGen, Inc., Cambridge, Massachusetts

Requests for reprints: Christopher P. Leamon, Endocyte, Inc., 3000 Kent Avenue, Suite A1-100, West Lafayette, IN 47906. Phone: 765-463-7175; Fax: 765-463-9271; E-mail: Chrisleamon{at}endocyte.com.

EC131, a new folate receptor (FR)–targeted drug conjugate, was prepared by covalently attaching the vitamin folic acid (FA) to a potent microtubule-inhibiting agent, maytansinoid DM1, via an intramolecular disulfide bond. When tested on cells in culture, EC131 was found to retain high affinity for FR-positive cells and to provide FR-specific cytotoxicity with an IC₅₀ in the low nanomolar range. The activity of EC131 was completely blocked in the presence of an excess of free FA, and no activity was detected against FR-negative cells. When evaluated against s.c. FR-positive M109 tumors in BALB/c mice, EC131 showed marked antitumor efficacy. Furthermore, this therapeutic effect occurred in the apparent absence of weight loss or noticeable organ tissue degeneration. In contrast, no significant antitumor activity was observed in EC131-treated animals that were codosed with an excess of FA, thus demonstrating the targeted specificity of the in vivo activity. EC131 also showed marked antitumor activity against FR-positive human KB tumors, but not against FR-negative A549 tumors, in nude mice with no evidence of systemic toxicity during or after the therapy. In contrast, therapy with the free maytansinoid drug (in the form of DM1-S-Me) proved not to be effective against the KB model when administered at its maximum tolerated dose (MTD). Taken together, these results indicate that EC131 is a highly potent agent capable of producing therapeutic benefit in murine tumor models at sub-MTD levels. [Cancer Res 2007;67(13):6376–82]

This article has been cited by other articles:

				C. P. Leamon, J. A. Reddy, M. Vetzel, R. Dorton, E. Westrick, N. Parker, Y. Wang, and I. Vlahov Folate Targeting Enables Durable and Specific Antitumor Responses from a Therapeutically Null Tubulysin B Analogue Cancer Res., December 1, 2008; 68(23): 9839 - 9844. [Abstract] [Full Text] [PDF]

				C. P. Leamon, J. A. Reddy, R. Dorton, A. Bloomfield, K. Emsweller, N. Parker, and E. Westrick Impact of High and Low Folate Diets on Tissue Folate Receptor Levels and Antitumor Responses Toward Folate-Drug Conjugates J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 918 - 925. [Abstract] [Full Text] [PDF]